Toronto Dominion Bank Acquires 1,022 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Toronto Dominion Bank increased its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 4.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,622 shares of the company’s stock after purchasing an additional 1,022 shares during the quarter. Toronto Dominion Bank’s holdings in Apellis Pharmaceuticals were worth $739,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals in the third quarter worth about $27,000. True Wealth Design LLC bought a new position in Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new position in Apellis Pharmaceuticals in the 3rd quarter worth approximately $56,000. KBC Group NV lifted its position in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares during the last quarter. Finally, nVerses Capital LLC boosted its stake in shares of Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on APLS. Needham & Company LLC dropped their price target on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. JPMorgan Chase & Co. dropped their price objective on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Morgan Stanley started coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 target price on the stock. Finally, Robert W. Baird dropped their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:APLS opened at $33.66 on Tuesday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a fifty day simple moving average of $29.78 and a two-hundred day simple moving average of $34.67. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -16.58 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.17) EPS. On average, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).